Global Cancer Drug Therapy Market Research Report 2019

2 Global Cancer Drug Therapy Quarterly Market Size Analysis

• 2.1 Cancer Drug Therapy Business Impact Assessment - COVID-19
  • 2.1.1 Global Cancer Drug Therapy Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
  • 2.1.2 Global Cancer Drug Therapy Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
• 2.2 Global Cancer Drug Therapy Quarterly Market Size 2020-2021
• 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
  • 2.3.1 Drivers
  • 2.3.2 Restraints
  • 2.3.3 Opportunities
  • 2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

• 3.1 Global Cancer Drug Therapy Quarterly Market Size by Manufacturers, 2019 VS 2020
• 3.2 Global Cancer Drug Therapy Factory Price by Manufacturers
• 3.3 Location of Key Manufacturers Cancer Drug Therapy Manufacturing Factories and Area Served
• 3.4 Date of Key Manufacturers Enter into Cancer Drug Therapy Market
• 3.5 Key Manufacturers Cancer Drug Therapy Product Offered
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Cancer Drug Therapy Segments, By Type

• 4.1 Introduction
  • 1.4.1 Targeted Therapy
  • 1.4.2 Chemotherapy
  • 1.4.3 Immunotherapy
• 4.2 By Type, Global Cancer Drug Therapy Market Size, 2019-2021
  • 4.2.1 By Type, Global Cancer Drug Therapy Market Size by Type, 2020-2021
  • 4.2.2 By Type, Global Cancer Drug Therapy Price, 2020-2021

5 Impact of Covid-19 on Cancer Drug Therapy Segments, By Application

• 5.1 Overview
  • 5.5.1 Angiogenesis Inhibitors
  • 5.5.2 mTOR Inhibitors
  • 5.5.3 Monoclonal Antibodies
  • 5.5.4 Cytokine Immunotherapy (IL-2)
• 5.2 By Application, Global Cancer Drug Therapy Market Size, 2019-2021
  • 5.2.1 By Application, Global Cancer Drug Therapy Market Size by Application, 2019-2021
  • 5.2.2 By Application, Global Cancer Drug Therapy Price, 2020-2021

6 Geographic Analysis

• 6.1 Introduction
• 6.2 North America
  • 6.2.1 Macroeconomic Indicators of US
  • 6.2.2 US
  • 6.2.3 Canada
• 6.3 Europe
  • 6.3.1 Macroeconomic Indicators of Europe
  • 6.3.2 Germany
  • 6.3.3 France
  • 6.3.4 UK
  • 6.3.5 Italy
• 6.4 Asia-Pacific
  • 6.4.1 Macroeconomic Indicators of Asia-Pacific
  • 6.4.2 China
  • 6.4.3 Japan
  • 6.4.4 South Korea
  • 6.4.5 India
  • 6.4.6 ASEAN
• 6.5 Rest of World
  • 6.5.1 Latin America
  • 6.5.2 Middle East and Africa

7 Company Profiles

• 7.1 Amgen / Allergan
  • 7.1.1 Amgen / Allergan Business Overview
  • 7.1.2 Amgen / Allergan Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.1.3 Amgen / Allergan Cancer Drug Therapy Product Introduction
  • 7.1.4 Amgen / Allergan Response to COVID-19 and Related Developments
• 7.2 Argos Therapeutics
  • 7.2.1 Argos Therapeutics Business Overview
  • 7.2.2 Argos Therapeutics Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.2.3 Argos Therapeutics Cancer Drug Therapy Product Introduction
  • 7.2.4 Argos Therapeutics Response to COVID-19 and Related Developments
• 7.3 AstraZeneca
  • 7.3.1 AstraZeneca Business Overview
  • 7.3.2 AstraZeneca Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.3.3 AstraZeneca Cancer Drug Therapy Product Introduction
  • 7.3.4 AstraZeneca Response to COVID-19 and Related Developments
• 7.4 Aveo Pharmaceuticals
  • 7.4.1 Aveo Pharmaceuticals Business Overview
  • 7.4.2 Aveo Pharmaceuticals Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.4.3 Aveo Pharmaceuticals Cancer Drug Therapy Product Introduction
  • 7.4.4 Aveo Pharmaceuticals Response to COVID-19 and Related Developments
• 7.5 Bayer
  • 7.5.1 Bayer Business Overview
  • 7.5.2 Bayer Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.5.3 Bayer Cancer Drug Therapy Product Introduction
  • 7.5.4 Bayer Response to COVID-19 and Related Developments
• 7.6 Exelixis
  • 7.6.1 Exelixis Business Overview
  • 7.6.2 Exelixis Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.6.3 Exelixis Cancer Drug Therapy Product Introduction
  • 7.6.4 Exelixis Response to COVID-19 and Related Developments
• 7.7 Incyte
  • 7.7.1 Incyte Business Overview
  • 7.7.2 Incyte Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.7.3 Incyte Cancer Drug Therapy Product Introduction
  • 7.7.4 Incyte Response to COVID-19 and Related Developments
• 7.8 Merck
  • 7.8.1 Merck Business Overview
  • 7.8.2 Merck Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.8.3 Merck Cancer Drug Therapy Product Introduction
  • 7.8.4 Merck Response to COVID-19 and Related Developments
• 7.9 Roche
  • 7.9.1 Roche Business Overview
  • 7.9.2 Roche Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.9.3 Roche Cancer Drug Therapy Product Introduction
  • 7.9.4 Roche Response to COVID-19 and Related Developments
• 7.10 Bristol-Myers Squibb
  • 7.10.1 Bristol-Myers Squibb Business Overview
  • 7.10.2 Bristol-Myers Squibb Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.10.3 Bristol-Myers Squibb Cancer Drug Therapy Product Introduction
  • 7.10.4 Bristol-Myers Squibb Response to COVID-19 and Related Developments
• 7.11 Eisai
  • 7.11.1 Eisai Business Overview
  • 7.11.2 Eisai Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.11.3 Eisai Cancer Drug Therapy Product Introduction
  • 7.11.4 Eisai Response to COVID-19 and Related Developments
• 7.12 Exelixis
  • 7.12.1 Exelixis Business Overview
  • 7.12.2 Exelixis Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.12.3 Exelixis Cancer Drug Therapy Product Introduction
  • 7.12.4 Exelixis Response to COVID-19 and Related Developments
• 7.13 Genentech (Roche)
  • 7.13.1 Genentech (Roche) Business Overview
  • 7.13.2 Genentech (Roche) Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.13.3 Genentech (Roche) Cancer Drug Therapy Product Introduction
  • 7.13.4 Genentech (Roche) Response to COVID-19 and Related Developments
• 7.14 Novartis
  • 7.14.1 Novartis Business Overview
  • 7.14.2 Novartis Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.14.3 Novartis Cancer Drug Therapy Product Introduction
  • 7.14.4 Novartis Response to COVID-19 and Related Developments
• 7.15 Pfizer
  • 7.15.1 Pfizer Business Overview
  • 7.15.2 Pfizer Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.15.3 Pfizer Cancer Drug Therapy Product Introduction
  • 7.15.4 Pfizer Response to COVID-19 and Related Developments
• 7.16 Prometheus Labs
  • 7.16.1 Prometheus Labs Business Overview
  • 7.16.2 Prometheus Labs Cancer Drug Therapy Quarterly Production and Revenue, 2020
  • 7.16.3 Prometheus Labs Cancer Drug Therapy Product Introduction
  • 7.16.4 Prometheus Labs Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

• 8.1 Cancer Drug Therapy Supply Chain Analysis
  • 8.1.1 Cancer Drug Therapy Supply Chain Analysis
  • 8.1.2 Covid-19 Impact on Cancer Drug Therapy Supply Chain
• 8.2 Distribution Channels Analysis
  • 8.2.1 Cancer Drug Therapy Distribution Channels
  • 8.2.2 Covid-19 Impact on Cancer Drug Therapy Distribution Channels
  • 8.2.3 Cancer Drug Therapy Distributors
• 8.3 Cancer Drug Therapy Customers

9 Key Findings

10 Appendix

• 10.1 About Us